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a Third-Generation Balloon-Expandable
Valve in Degenerated Mitral Bioprosthesis
David Jochheim, MD,*y Alexander Khandoga, MD,* Axel Bauer, MD,*y Moritz Baquet, MD,* Hans Theiss, MD,*y
Jan Schenzle, MD,* Joerg Hausleiter, MD,*y Steffen Massberg, MD,*y Julinda Mehilli, MD*yA 84-year-old woman with known hepaticcancer, severe pulmonary hypertension,and atrial ﬁbrillation on phenprocoumon
was admitted for recurrent congestive heart failureFIGURE 1 Procedural Angiograms
(A, B) Transseptal puncture and correct positioning of the valve within t
rapid pacing. (F) Final results of SAPIEN 3 valve within the Perimount M
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due to severe insufﬁciency (Figures 1A to 1F). Onhe bioprosthesis. (C to E) Balloon inﬂation and valve expansion under
agna bioprosthesis (Edwards Lifesciences). See Online Video 1.
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FIGURE 2 Echocardiographic Measurements
Echocardiographic measurements of mitral bioprosthesis before (A, B) and after (C, D) initial implantation of the SAPIEN 3 valve (Edwards
Lifesciences) in mitral position. Prosthesis oriﬁce area before (E) and after (F) the procedure.
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e242admission, the patient was in New York Heart Associ-
ation (NYHA) functional class IV with concomitant leg
edema. Echocardiography demonstrated good left
ventricular function, a dilated left atrium, and severe
mitral valve stenosis with a mean gradient of 29
mm Hg and a valve oriﬁce area of 1.01 cm2 (Figures
2A and 2B). Computed tomography examination
showed a calciﬁed bioprosthesis with a calculatedinner prosthesis area of 3.7 cm2. Based on an estimated
EuroSCORE II of 10.62%, the heart team recommended
a transcatheter valve-in-valve procedure with a
23-mm SAPIEN 3 balloon-expandable valve (BEV) via
a percutaneous transseptal approach. With the patient
under general anesthesia and with transesophageal
echocardiographic guidance, we performed a success-
ful implantation of a 23-mm SAPIEN 3 (procedural
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e243angiograms). Post-implantation echocardiography
revealed a mean gradient of 6 mm Hg, a mitral valve
oriﬁce area of 2.4 cm2 (Figures 2C to 2F), and the
absence of any periprosthetic regurgitation (Online
Video 1). Seven days after index procedure, the
patient was discharged with signiﬁcant physical
improvements and NYHA functional class II.
This interesting case is the ﬁrst description of
a transseptal valve-in-valve procedure with the third-
generation BEV in a degenerated mitral bioprosthesis.
Valve-in-valve implantation in the mitral position isbecoming an increasingly accepted treatment option
for patients deemed unsuitable for a redo operation
(1,2). With this case, we conﬁrm the safety and
hemodynamic efﬁcacy of transseptal transcatheter
implantation with the SAPIEN 3 BEV.
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APPENDIX For a supplemental video,
please see the online version of this article.
